Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146898 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Enric Monreal und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Universitario Ramón y Cajal, Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), I…. Hauptthemen laut MEDLINE: Biomarkers, Multiple Sclerosis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, La Red Española de Enfermedades Inflamatorias (REI), La Red Española de Esclerosis Múltiple (REEM).
Abstract (Originalsprache)
The combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific IgM oligoclonal bands (LS-OCMB) with different forms of disability worsening, such as relapse-associated worsening (RAW), active progression independent of relapse activity (aPIRA), and non-active PIRA (naPIRA). A total of 535 patients with MS were included, all sampled within one year of disease onset. Biomarkers were quantified using single-molecule array and immunoblotting techniques, and CSF cell subsets were analyzed by flow cytometry. High sNfL z-scores and LS-OCMB positivity were independently associated with increased risk of RAW and aPIRA, collectively termed inflammatory-associated worsening (IAW), while elevated sGFAP levels predicted naPIRA. Patients with both high sNfL and LS-OCMB positivity had the highest risk of IAW. Among LS-OCMB–positive patients, higher regulatory T cell percentages were associated with lower sNfL levels, suggesting a protective role. Conversely, in LS-OCMB–negative patients, sNfL levels correlated with CSF C3 concentrations. These findings support the complementary role of sNfL, sGFAP, and LS-OCMB in identifying distinct mechanisms of disease worsening and may inform early personalized management strategies in MS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Hospital Universitario Ramón y Cajal, Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), IRYCIS, Universidad de Alcalá, 28034 Madrid, Spain.
- Department of Immunology, Hospital Universitario Ramón y Cajal, Red Española de Esclerosis Múltiple (REEM), Red de Enfermedades Inflamatorias (REI), IRYCIS, Universidad de Alcalá, 28034 Madrid, Spain.
- Department of Neurology, Hospital Universitario Getafe, Universidad Europea de Madrid, 28905 Madrid, Spain.
- Department of Neurology, Hospital Universitario Gregorio Marañón, 28007 Madrid, Spain.
- Department of Neurology, Hospital Universitario Príncipe de Asturias, 28805 Alcalá de Henares, Spain.
- Neuroimmunology and Multiple Sclerosis Unit, Neurodegeneration and Neuroinflammation Research Group, Girona Biomedical Research Institute (IDIBGI), Dr. Josep Trueta University Hospital, 17001 Catalonia, Spain.
ORCID-Profile: Enric Monreal, José Ignacio Fernández-Velasco, Susana Sainz de la Maza, Noelia Villarrubia, Juan Pablo Cuello, Alexander Rodero-Romero, Juan Luís Chico-García, Fernando Rodríguez-Jorge, José Manuel García-Domínguez, Sara Llufriu, Manuel Comabella, Xavier Montalban, Jaime Masjuan, Lucienne Costa-Frossard, Luisa María Villar
Förderung
- Instituto de Salud Carlos III
- La Red Española de Enfermedades Inflamatorias (REI)
- La Red Española de Esclerosis Múltiple (REEM)
- European Union
Zitieren
APA
Monreal, E., Fernández-Velasco, J. I., Sainz de la Maza, S., Espiño, M., Villarrubia, N., Roldán-Santiago, E., Aladro, Y., Cuello, J. P., Ayuso-Peralta, L., Rodero-Romero, A., Chico-García, J. L., Rodríguez-Jorge, F., Quiroga-Varela, A., Rodríguez-Martín, E., Pilo de la Fuente, B., Martín-Ávila, G., Martínez-Ginés, M. L., García-Domínguez, J. M., Rubio, L., …, & Villar, L. M. (2025). Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146898
Vancouver
Monreal E, Fernández-Velasco JI, Sainz de la Maza S, Espiño M, Villarrubia N, Roldán-Santiago E, et al. Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146898
BibTeX
@article{Monreal2025,
author = {Monreal, Enric and Fernández-Velasco, José Ignacio and Sainz de la Maza, Susana and Espiño, Mercedes and Villarrubia, Noelia and Roldán-Santiago, Ernesto and Aladro, Yolanda and Cuello, Juan Pablo and Ayuso-Peralta, Lucía and Rodero-Romero, Alexander and Chico-García, Juan Luís and Rodríguez-Jorge, Fernando and Quiroga-Varela, Ana and Rodríguez-Martín, Eulalia and Pilo de la Fuente, Belén and Martín-Ávila, Guillermo and Martínez-Ginés, María Luisa and García-Domínguez, José Manuel and Rubio, Lluïsa and Llufriu, Sara and Comabella, Manuel and Montalban, Xavier and Álvarez-Bravo, Gary and Veiga-González, José Luís and Masjuan, Jaime and Costa-Frossard, Lucienne and Villar, Luisa María},
title = {Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146898}
}
EUVIMED